Back to Journals » OncoTargets and Therapy » Volume 6

Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers

Total article views   HTML views PDF downloads Totals
20,672 Dovepress* 14,793+ 3,562 18,355
PubMed Central* 5,879 1,950 7,829
Totals 20,672 5,512 26,184
*Since 5 November 2013
+Since July 2016
Total mentioned Facebook Delicious Reddit Twitter Others
5 0 0 0 0 5

View citations on PubMed and Google Scholar